Clinical Trials Logo

Prader-Willi Syndrome clinical trials

View clinical trials related to Prader-Willi Syndrome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05701774 Active, not recruiting - Clinical trials for Prader-Willi Syndrome

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

Start date: January 31, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.

NCT ID: NCT05322096 Active, not recruiting - Clinical trials for Prader-Willi Syndrome

Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome

Start date: September 22, 2022
Phase: Phase 2
Study type: Interventional

RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management. This will be the first Phase 2, proof-of-concept study using RGH-706 and is the third study in the clinical development program for RGH-706. The aim of this study is to evaluate the efficacy, safety, and tolerability of RGH-706 in patients with Prader-Willi Syndrome (PWS).

NCT ID: NCT04697381 Active, not recruiting - Clinical trials for Prader-Willi Syndrome

Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS

Start date: February 6, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter, open label, multi cohort study to evaluate the efficacy and safety of somatropin in a cohort of Japanese participants with PWS.

NCT ID: NCT04257929 Active, not recruiting - Clinical trials for Prader-Willi Syndrome

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Start date: December 9, 2020
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Prader Willi syndrome (PWS) ages 6 to 65 years.

NCT ID: NCT03848481 Active, not recruiting - Clinical trials for Prader-Willi Syndrome

CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)

Start date: November 23, 2020
Phase: Phase 2
Study type: Interventional

This study aims to examine the feasibility and safety of cannabidivarin (CBDV) as a treatment for children and young adults with PWS.

NCT ID: NCT01613495 Active, not recruiting - Clinical trials for Prader Willis Syndrome

Ghrelin Suppression by Octreotide in Prader-Willi

Start date: August 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to learn more about how octreotide (Sandostatin LAR® Depot) affects levels of ghrelin, hunger, and body weight in people with Prader-Willi Syndrome.

NCT ID: NCT01520467 Active, not recruiting - Clinical trials for Prader-Willi Syndrome

Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome

ANASILPRA
Start date: April 2012
Phase: N/A
Study type: Interventional

There is currently no drug with pediatric marketing authorization capable of limiting the advance in bone maturation of children with aggressive adrenarche. Estrogens are the principal actors involved in bone maturation and premature epiphyseal fusion. Aromatase inhibitors, used for the treatment of hormone-dependent cancers, block the transformation of androgens into estrogens. Third generation inhibitors, of which Anastrozole is one, appear to be well tolerated in children and are sometimes used within the framework of clinical trials to limit bone maturation and improve prognosis with respect to final size, notably in children treated with growth hormone (GH) due to a GH deficit. Nevertheless, the data reported are based on small sample sizes and do not include children with pathological adrenarche.